FDA approved pembrolizumab for 3rd-line PMBCL in adult and pediatric patients
- On June 13, 2018, the US FDA has granted accelerated approval to pembrolizumab (KeytrudaⓇ, Merck & Co. Inc.) for the treatment of adult and pediatric patients with primary mediastinal large B-cell lymphoma (PMBCL), relapsed after two or more prior lines of prior therapy.
Trackbacks & Pingbacks
[…] Primary Mediastinal Large B-Cell Lymphoma (PMBCL): […]
Leave a Reply
Want to join the discussion?Feel free to contribute!